Our Mission
Freenome is an early cancer detection company developing blood-based screening tests to detect cancer when it is most treatable. The company's Personalized Cancer Detection approach combines multiomics, artificial intelligence and machine learning to develop screening tests tailored to the biology of individual cancers and the needs of specific patient populations.
The company’s first commercial-stage test, SimpleScreen™ CRC for colorectal cancer, is under review by the U.S. Food and Drug Administration (FDA). Freenome is partnering with Abbott Cancer Diagnostics (formerly Exact Sciences) to bring SimpleScreen CRC to market following FDA approval, with Abbott taking the lead on commercialization. The companies are also collaborating on joint development efforts for future generations of the test. Beyond colorectal cancer, Freenome continues to advance a pipeline of next-generation, non-invasive screening tests for additional cancer indications as part of its mission to expand participation in cancer screening.